Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants.

Trial Profile

Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Hib vaccine conjugate (Primary) ; DTaP vaccine; DTaP-hepatitis B-poliovirus vaccine; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Feb 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrial.gov record.
    • 11 Jan 2013 Planned end date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Planned end date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top